Bollinger Innovations (BINI), formerly Mullen Automotive, trades on OTC Markets after being delisted from Nasdaq in October 2025, with shares priced below $0.10 and a market capitalization of approximately $1 million. The company reported a net loss of $472.94 million on trailing twelve-month revenue of just $9.34 million, reflecting severe operating inefficiencies and negative gross margins exceeding 1,400% in its most recent fiscal year.

Faraday Future Intelligent Electric (FFAI) shares have fallen approximately 84.7% over the last 30 days, dropping from $28.56 on July 10 to $4.37 as of August 10, 2026. A 150:1 reverse stock split, effective July 24, 2026, triggered sharp selling pressure as the company moved to maintain Nasdaq listing compliance.

MicroAlgo Inc. ( MLGO ) currently trades near $4.08, making the $8 target a potential upside of roughly 96% from current levels. The company returned to profitability in fiscal 2025, posting net income of approximately $16.3 million, a 195% year-over-year improvement, alongside an exceptionally low price-to-earnings (P/E) ratio below 2.

Starling Oncology, Inc. recently raised its full-year 2026 revenue guidance to a range of $650 million to $670 million, signaling confidence in operational scaling and contract expansion. Analyst consensus stands at a "Strong Buy" rating with an average price target of approximately $9.00, reflecting optimism around the company's positioning in value-based cancer care.

Ulta Beauty shares surged approximately 17% over the past 30 days, climbing from $469.20 on July 10 to $548.66 on August 10, dramatically outperforming the broader market. The rally reflects a confluence of catalysts: strong first-quarter fiscal 2026 earnings, a raised full-year profit outlook, aggressive share buybacks, and newly disclosed institutional accumulation.

Arxis (ARXS) surged approximately 37.6% over the past 30 days, rallying from $41.79 on July 10 to $57.51 by August 10, driven by a blockbuster second-quarter earnings report. The company reported Q2 2026 revenue of $501 million, up 25% year-over-year, and adjusted EPS of $0.28, soundly beating consensus estimates that had called for a loss of $0.07 per share.

Cognizant Technology Solutions (CTSH) surged approximately 37% over the last 30 days, climbing from $42.57 on July 10 to $58.31 on August 10. The rally was ignited by a strong Q2 2026 earnings report on July 29, featuring better-than-expected revenue, raised full-year EPS guidance, and a $2 billion share buyback authorization.

Regencell Bioscience Holdings (RGC) declined approximately 10.2% over the last 30 days, from $5.88 on July 10 to $5.28 on August 10, 2026. The 30-day slide extends a far steeper quarterly collapse of roughly 81%, with the stock falling from $27.32 in mid-May to current levels near $5.

NIO Inc. (NYSE: NIO) closed at approximately $4.82 on August 10, 2026, meaning a move to $10 would require more than a 100% gain from current levels. The $10 price target sits at the high end of Wall Street analyst estimates — the consensus average is near $7.34, with the most optimistic forecasts reaching $10.04.

ROMA shares gained approximately 12% over the past 30 days, rising from $8.47 to $9.51, propelled by a strategic pivot into AI and high-performance computing infrastructure. Over the last quarter, the stock similarly advanced roughly 12%, though the period included sharp volatility as the company unveiled multiple AI-related initiatives alongside a $200 million at-the-market equity offering program.

Price target in focus: $22 per share, representing the lowest Wall Street analyst target and roughly 75% upside from recent trading levels near $12.59. Strongest bullish catalyst: TONMYA, the first FDA-approved fibromyalgia treatment in over 15 years, posted $11 million in Q2 2026 net sales — nearly tripling quarter-over-quarter — with prescriptions doubling and refills surging 207%.

Bending Spoons (BSP) closed at $51.43 during regular trading, surging +15.70% from the prior session's close of $44.45. The rally was fueled by mounting anticipation ahead of the company's Q2 2026 earnings report, scheduled for release on August 13 before the U.S. market opens.

ATI Inc. shares surged approximately 22% over the last 30 days, driven by a standout Q2 2026 earnings report that beat estimates on both revenue and adjusted EPS. The company raised its full-year 2026 guidance across all key metrics, including adjusted EBITDA, adjusted EPS, and adjusted free cash flow, signaling confidence in sustained momentum.

JD.com (JD) shares surged approximately 17% over the last 30 days, climbing from $28.20 to around $32.96 as of early August 2026. The rally has been driven by growing analyst optimism ahead of the company's Q2 2026 earnings release, with Bank of America projecting adjusted net profit of RMB 85 billion — well above consensus estimates.

Target price in focus: $5.00 per share, representing roughly 75% upside from recent trading levels around $2.86 and sitting within the range of Wall Street analyst price targets. Strongest bullish factor: The company's Solana (SOL) treasury strategy ties DFDV's fortunes directly to the Solana ecosystem, and SOL per share grew 108% year-over-year as of mid-2026, driven by organic staking yield and strategic debt buybacks.

Price Target in Focus: The $30 level sits squarely within the Wall Street consensus, with analyst targets ranging from $20 to $38 and the average hovering near $28–$29. Bitcoin Treasury Model: Strive holds approximately 13,741 Bitcoin, making its stock price heavily dependent on Bitcoin's performance and the company's ability to accumulate additional coins at favorable prices.

Price Target: The $1.00 level represents the sole published analyst price target for NWBO, implying an upside of roughly 400–500% from its recent trading range near $0.18–$0.23. Strongest Bullish Factor: A potential regulatory approval of DCVax-L by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) would be a transformative catalyst, validating the company's dendritic cell immunotherapy platform.

JBS swung to a net loss of $102 million in Q2 2026, reversing a $528 million profit from the same quarter last year, driven by non-recurring charges and persistent margin pressure in North American beef. Revenue reached an all-time quarterly record of $23.9 billion , up 14% year-over-year and comfortably ahead of the $23.1 billion consensus estimate, reflecting strong global protein demand and higher selling prices.

Revenue surged to $31.52 million , a 2,617% increase from $1.16 million in the same quarter last year, but fell short of the consensus estimate of approximately $35 million. Earnings per share (EPS) came in at -$0.77 , missing analyst expectations that ranged from -$0.26 to -$0.37, largely driven by a $125.9 million loss on involuntary conversion tied to satellite-related assets.

Net profit reached $1.205 billion, compared with just $58 million in the same quarter a year earlier. Revenue surged 42% year-over-year to $6.574 billion, surpassing analyst estimates compiled by LSEG of approximately $6.10 billion.